Fundraising FoxEos SENOLYTIX
Houston, US · Founded 2024 · Delaware corporation · 1 known investors
Find your way into Eos SENOLYTIX
Sign up to see every warm intro you have to Eos SENOLYTIX
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Eos SENOLYTIX team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Eos SENOLYTIX develops senolytic peptides designed to restore cellular balance in aged or senescent cells across body organs, focusing on gerotherapeutics. The company targets age-related conditions through proprietary approaches to cellular rejuvenation.
Founders & leadership
Eos SENOLYTIX was founded in 2024 by Kevin Slawin, M.D..
KS
Kevin Slawin, M.D.Founder and CEODr. Kevin Slawin is founder and CEO of Eos SENOLYTIX, a longevity company developing senolytic peptides for age-related conditions. He previously co-founded Bellicum Pharmaceuticals, which went public in 2014, and holds multiple patents in prostate cancer diagnostics and immunotherapy technologies.
Board
JW
Jerold WinogradBoard director
FB
Frank Bartlett McGuyerBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$750K disclosed across 1 round · 2026
▶$750KraisedAug 2026 · 2 investors · PharmaceuticalsRule 506(b)
▶$750KraisedAug 2026 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Kevin Mark SlawinExecutive Officer, Director
- Frank Bartlett McGuyerDirector
- Jerold WinogradDirector
- Offering amount
- $25M
- Amount sold
- $750K
- Minimum investment
- $250K
- Sales commissions
- $1.4M
- Placement agents
- Floww Private Markets US Inc., Floww Private Markets US Inc., Floww Private Markets US Inc.
- First sale
- Jun 2026
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Phoenix SENOLYTIXPhoenix SENOLYTIX develops gene therapies targeting senescent cells to address aging-related conditions. The company utilizes its ApoptiCIDe-CE™ platform technology, validated in human patients, to eliminate unwanted cells in the body.
CenegenicsCenegenics is a physician-led age management and performance health system that uses diagnostics and data-driven interventions to help individuals optimize strength, cognition, metabolic health, and longevity. The company serves individuals seeking personalized, medically grounded approaches to extending peak physical and cognitive performance.
Companies working in the same space as Eos SENOLYTIX.
Frequently asked questions
- What does Eos SENOLYTIX do?
- Eos SENOLYTIX develops senolytic peptides designed to restore cellular balance in aged or senescent cells across body organs, focusing on gerotherapeutics. The company targets age-related conditions through proprietary approaches to cellular rejuvenation.
- Who founded Eos SENOLYTIX?
- Eos SENOLYTIX was founded by Kevin Slawin, M.D. in 2024.
- Who are Eos SENOLYTIX's investors?
- Eos SENOLYTIX's investors include Rapha Capital Management, LLC.
- How much funding has Eos SENOLYTIX raised?
- Eos SENOLYTIX has disclosed $750K raised across 1 round.
- Where is Eos SENOLYTIX headquartered?
- Eos SENOLYTIX is headquartered in Houston, US.